Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Large B-cell lymphoma imprints dysfunctional immune phenotype that persists years after treatment

ABSTRACT: Large B-cell lymphoma imprints dysfunctional immune phenotype that persists years after treatment

PROVIDER: PRJNA1162855 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Large B-cell lymphoma imprints dysfunctional immune phenotype that persists years after treatment

Project description:Comprehensive study of the immune fingerprint of lymphoma and immunotherapy on DLBCL survivors

2025-09-01 | GSE277575 | GEO

Large B-cell lymphoma imprints dysfunctional immune phenotype that persists years after treatment

Project description:anaylsis of the immunophenotype and functional immune impairment in DLBCL survivors

| PRJEB80155 | ENA

Replication-coupled passive DNA demethylation for the erasure of genome imprints in mice

Project description:Genome-wide DNA demethylation, including the erasure of genome imprints, in primordial germ cells (PGCs), is critical as a first step for creating the totipotent epigenome in the germ line. Here, we provide evidence that contrary to the prevailing model involving active DNA demethylation, imprint erasure in mouse PGCs occurs in a manner consistent with replication-coupled passive DNA demethylation: PGCs erase imprints during their rapid proliferation with little de novo as well as maintenance DNA methylation potential and no major chromatin alterations. Our findings necessitate the re-evaluation of and provide novel insights into the mechanism of genome-wide DNA demethylation in PGCs. We performed expression analysis of primordial germ cells (PGCs) at embryonic days 10.5-13.5. Because the number of PGCs available at these stages were low, cDNAs were amplified by the method that we previously published (Kurimoto et al. 2006, NAR 34: e42 (PMID 16547197)). To include analysis of PGC gene expression at E9.5, we re-normalized the data from our E9.5 PGC samples (GSM744103, GSM744104) from our previous publication (Hayashi et al., 2011, Cell 146: 519-32 (PMD 21820164)) together with the data from this submission.

2013-03-04 | E-GEOD-40412 | biostudies-arrayexpress

IMPRINTS-CETSA Venetoclax in Kasumi-1 cells, 6h incubation

Project description:IMPRINTS-CETSA data acquisition of Kasumi-1 cells treated with Vehicle (DMSO), Venetoclax, Decitabine, Azacitidine and Azacitidine+Venetoclax using TMT 16 plex.

2024-10-23 | PXD056189 | Pride

IMPRINTS-CETSA Venetoclax in Kasumi-1 cells, 1h incubation

Project description:IMPRINTS-CETSA data acquisition of Kasumi-1 cells treated with Vehicle (DMSO), Venetoclax, Decitabine, Azacitidine and Azacitidine+Venetoclax using TMT 16 plex.

2024-10-23 | PXD056183 | Pride

Rescue Of Dysfunctional Autophagy By Peptide IDR-1018 Attenuates Hyperinflammatory Phenotype Of Cystic Fibrosis Cells (RNA-seq)

Project description:Genome-wide gene expression was measured in peripheral blood mononuclear cells (PBMCs) from patients with cystic fibrosis (CF) after treatment in vitro with the flagellin protein fliC, and/or synthetic peptide IDR-1018 to assess patterns of gene expression. The patterns of gene expression suggest that CF cells have a hyperinflammatory phenotype including dysfunctional autophagy processes. The synthetic peptide IDR-1018 attentuates this hyperinflammatory phenotype. Total RNA was obtained from PBMCs obtained from CF patients after treatment with the fliC flagellin protein (that is known to play a role in CF lung inflammation), and/or the peptide IDR-1018 that has anti-inflammatory properties. Comparison of genes and pathways affected by these treatments indicated the role of autophagy process in CF disease.

2012-11-20 | E-GEOD-35394 | biostudies-arrayexpress

IMPRINTS-CETSA Docetaxel and Paclitaxel in MCF-7 cells, 8h incubation

Project description:IMPRINTS-CETSA data acquisition of MCF-7 cells treated with Vehicle (DMSO), Docetaxel or Paclitaxel using TMT 10 plex.

2024-10-23 | PXD056176 | Pride

IMPRINTS-CETSA Alpelisib and Buparlisib in MCF-7 cells, 6h incubation

Project description:IMPRINTS-CETSA data acquisition of MCF-7 cells treated with Vehicle (DMSO), Alpelisib and Buparlisib using TMT 10 plex.

2024-10-23 | PXD056197 | Pride

IMPRINTS-CETSA Alpelisib and Buparlisib in MCF-7 cells, 1h incubation

Project description:IMPRINTS-CETSA data acquisition of MCF-7 cells treated with Vehicle (DMSO), Alpelisib and Buparlisib using TMT 10 plex.

2024-10-23 | PXD056196 | Pride

IMPRINTS-CETSA Docetaxel and Paclitaxel in MCF-7 cells, 1h incubation

Project description:IMPRINTS-CETSA data acquisition of MCF-7 cells treated with Vehicle (DMSO), Docetaxel or Paclitaxel using TMT 10 plex.